A carregar...
Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120
BACKGROUND: Two randomized, double-blind, placebo-controlled trials (EPPIC-1 and EPPIC-2) investigated the efficacy and safety of AST-120, an oral spherical carbon adsorbent, in adults with chronic kidney disease (CKD). While the benefit of adding AST-120 to standard therapy was not supported by the...
Na minha lista:
| Publicado no: | Clin Exp Nephrol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Singapore
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5838144/ https://ncbi.nlm.nih.gov/pubmed/28741050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-017-1447-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|